Hoth Therapeutics has renamed to Rocket One Inc. and will trade under RKTO starting May 28, 2026, with HOTH ceasing on May 27. The rebrand, announced after a May 19 repositioning, centers the company on orbital compute and exclusive nanomagnetic AI chip licenses for space/defense, while legacy biotech programs continue via a subsidiary. Near-term catalysts include the ticker transition and potential licensing milestones.
The name/ticker change and announced strategic pivot to space/defense AI chip licensing provide a concrete, near-term reorientation signal that could unlock re-rating if licensing milestones and capital needs are manageable; however, early-stage tech and execution risk warrant caution.
RKTO could rerate higher over 12–24 months if space AI licensing progress and revenue visibility materialize.
This is a corporate development move: a strategic pivot and branding shift toward the space economy, with an exclusive AI chip license. It signals a potential multi-year transformation that could affect valuation if licensed tech advances, though near-term visibility remains uncertain.